Tagged Articles

Jauntier 2 articles

Deaths prompt Japanese drug officials to add new warnings to diabetes drugs

Ten deaths possibly linked to a new class of type 2 diabetes drugs is prompting Japanese drug regulators to request manufacturers to add new warnings to the drugs’ labels. The diabetes drugs, known as sodium-glucose cotransporter 2 (SGLT2) inhibitors, reduce blood sugar levels by eliminating excessive glucose from the body by inhibiting a protein that helps reabsorb sugar in the urine back into the blood. Since April, the Japanese health ministry has approved six SGLT2 inhibitors. Only three are approved in the U.S. – Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin). SGLT2 inhibitors have been associated with weight loss, which can ... Read More

Many newer diabetes drugs carry cancer risks

Within the past two decades, thanks in large part to diabetes experts lowering the blood sugar threshold, millions more Americans were labeled as diabetic and became eligible for medication to help regulate blood sugar levels. As a result, the diabetes drug industry boomed. Sales of diabetes drugs topped $23 billion, more than the revenues generated from the National Football League, Major League Baseball, and the National Basketball Association combined. But in the past decade, a Milwaukee Journal Sentinel and MedPage Today investigation discovered that none of the 30 new diabetes drugs were proven to improve diabetics’ risk for associated health ... Read More